Expand all sections

Damoctocog alfa pegol

Jivi

Extended indication Treatment and prophylaxis of bleeding in previously treated patients ≥12 years of age with haemophil
Therapeutic value Possible added value
Total cost 31,850,000.00
Registration phase Registration application pending

Product

Registration

Therapeutic value

Expected patient volume per year

Expected cost per patient per year

Potential total cost per year

Off label use

Indication extension

Other information